{
    "nct_id": "NCT03500328",
    "official_title": "A Pragmatic Trial to Evaluate the Intermediate-term Effects of Early, Aggressive Versus Escalation Therapy in People With Multiple Sclerosis",
    "inclusion_criteria": "* Aged 18-60 years\n* Meets 2017 McDonald criteria for relapsing-remitting MS [patients with clinically isolated syndrome (CIS) are not eligible]\n* Must be EITHER John Cunningham (JC) virus antibody negative or low positive (index antibody titer <0.9), OR negative for: Hepatitis B and C, tuberculosis\n* HIV negative\n* No chemotherapy in past year; if patient has prior history of chemotherapy or malignancy, documentation in chart explaining why potential risks of higher-efficacy therapy are justified\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 60 Years",
    "exclusion_criteria": "* Prior treatment with rituximab, ocrelizumab, ofatumumab, alemtuzumab, mitoxantrone or cladribine\n* Prior treatment with any other MS DMT for more than 6 months\n* Prior treatment with experimental aggressive therapies (e.g., T-cell vaccine, total lymphoid radiation, stem cells)\n* Treatment with teriflunomide within past 2 years (even for â‰¤ 6 months), unless rapid wash out done (i.e., with cholestyramine or activated charcoal)\n* Treatment in the past 6 months with any MS DMT\n* Prior treatment with any other investigational immune-modulating /suppressing drug for MS not listed above\n* Pregnant or breast-feeding\n* Women of child-bearing age who are planning or strongly considering conception during the study time frame",
    "miscellaneous_criteria": ""
}